Autism Spectrum Disorders Market By Disease (Autistic Disorder, Asperger Syndrome, Pervasive development disorder (PDD), Other), By Service (Behavioural Approaches, Early Intervention, Medication, Other Services), By Location (Hospitals, Education Counsel

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,380	300 Pages	Allied Market Research	September, 2022	ALMR17594363

Best Price Guarantee
Price	from $4,380
Length	300 Pages
Publisher	Allied Market Research
Published Date	September, 2022
SKU	ALMR17594363

Autism Spectrum Disorders Market By Disease (Autistic Disorder, Asperger Syndrome, Pervasive development disorder (PDD), Other), By Service (Behavioural Approaches, Early Intervention, Medication, Other Services), By Location (Hospitals, Education Counsellor Center, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global autism spectrum disorder treatment market was valued at $27,272.7 million in 2021, and is projected to reach $43,166.16 million by 2031, registering a CAGR of 4.6% from 2022 to 2031.

A class of sophisticated neurological illnesses known as autism spectrum disorder (ASD) is characterized by a wide range of behavioral patterns and difficulties with social interaction and communication. Compulsive behavior, incorrect social interaction, a learning handicap, anxiety, sensitivity to hearing, repetitive motions, and many other characteristics are among the key indications and symptoms of ASD.

The increase in prevalence of autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorders boost the growth of market. For instance, in November 2021, as per the study of Ben-Gurion University researchers and colleagues, it was found that, autism spectrum disorder diagnosis by 2.5 years of age leads to dramatic improvements in social symptoms as compared to those diagnosed later in life. Thus, rise in awareness about autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorder drive the growth of market.

Moreover, the increase in prevalence of autism spectrum disorder and rise in awareness regarding service of autism spectrum disorder are the key factors that drive the growth of autism spectrum disorder treatment market. For instance, in March 2022, as per the report of World Health Organization (WHO), it was estimated that worldwide about one in 100 children has autism spectrum disorder.

Furthermore, the increase in awareness about autism spectrum disorder and rise in contribution of government & non-government organizations to provide autism spectrum disorder diagnosis & service propel the growth of market. For instance, ASERT (Autism Services, Education, Resources and Training) is an organization of medical centers, and universities, announced the launch of Autism Awareness, Community Education and Support (AACES), a program designed to increase independence and decrease isolation among young people with autism spectrum disorder (ASD).

Moreover, the increase in R&D activities for development of advanced autism spectrum disorder treatment, advancements in diagnosis of disease, rise in U.S. food and drug administration (USFDA) approvals, and novel product launch in market by key players boost the market growth. For instance, in October 2021, Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, received clearance from the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND) application for lead candidate, AB-2004, a gut-targeted, molecular therapeutic for the service of irritability associated with autism spectrum disorder. Furthermore, advancements in autism spectrum disorder treatments such as online training platforms and mobile diseases for autism spectrum further contribute in market growth. However, the high cost of autism spectrum disorder treatment and lack of awareness about disease may hinder the growth of market.

The Autism spectrum disorder treatment market is segmented on the basis of service, disease, location and region. By service , the market is classified into behavioral approaches, early intervention, medication, and others.

Depending on disease, the market is classified into autistic disorder, asperger's syndrome, and pervasive development disorder (PDD).

By location, market is categorized into hospital, education counsellor center, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbvie Inc, Axial therapeutics, The Bristol Myers Squibb Company, Cognoa Inc, Curemark LLC, Dfusion Inc, EarliTec Diagnostics Inc, Jaguar Gene Therapy, Jazz Pharmaceuticals, Johnson & Johnson, Neurim Pharmaceuticals Ltd., Novartis AG, PaxMedica Inc, Pfizer Inc, Stalicla SA, Teva Pharmaceutical Industries Ltd. and Yamo Pharmaceuticals LLC.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autism spectrum disorders market analysis from 2021 to 2031 to identify the prevailing autism spectrum disorders market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the autism spectrum disorders market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global autism spectrum disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease

Autistic Disorder
Asperger Syndrome
Pervasive development disorder (PDD)
Other

By Service

Behavioural Approaches
Gender
Male
Female
Early Intervention
Gender
Male
Female
Medication
Gender
Male
Female
Other Services
Gender
Male
Female

By Location

Hospitals
Education Counsellor Center
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Abbvie Inc
Axial therapeutics
Bristol Myers Squibb Co.
Cognoa Inc
Curemark LLC
dfusion inc.
EarliTec Diagnostics Inc
Jazz Pharmaceuticals
Johnson & Johnson
Novartis AG

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Autistic Disorder; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.3 Asperger Syndrome; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country; 4.4 Pervasive development disorder (PDD); 4.4.1 Key market trends, growth factors and opportunities; 4.4.2 Market size and forecast, by region; 4.4.3 Market analysis by country; 4.5 Other; 4.5.1 Key market trends, growth factors and opportunities; 4.5.2 Market size and forecast, by region; 4.5.3 Market analysis by country
CHAPTER 5: AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Behavioural Approaches; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.2.4 Behavioural Approaches Autism Spectrum Disorders Market by Gender; 5.2.4.1 Male Market size and forecast, by region; 5.2.4.2 Female Market size and forecast, by region; 5.3 Early Intervention; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country; 5.3.4 Early Intervention Autism Spectrum Disorders Market by Gender; 5.3.4.1 Male Market size and forecast, by region; 5.3.4.2 Female Market size and forecast, by region; 5.4 Medication; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market analysis by country; 5.4.4 Medication Autism Spectrum Disorders Market by Gender; 5.4.4.1 Male Market size and forecast, by region; 5.4.4.2 Female Market size and forecast, by region; 5.5 Other Services; 5.5.1 Key market trends, growth factors and opportunities; 5.5.2 Market size and forecast, by region; 5.5.3 Market analysis by country; 5.5.4 Other Services Autism Spectrum Disorders Market by Gender; 5.5.4.1 Male Market size and forecast, by region; 5.5.4.2 Female Market size and forecast, by region
CHAPTER 6: AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Hospitals; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.3 Education Counsellor Center; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Others; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country
CHAPTER 7: AUTISM SPECTRUM DISORDERS MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Disease; 7.2.3 North America Market size and forecast, by Service; 7.2.3.1 North America Behavioural Approaches Autism Spectrum Disorders Market by Gender; 7.2.3.2 North America Early Intervention Autism Spectrum Disorders Market by Gender; 7.2.3.3 North America Medication Autism Spectrum Disorders Market by Gender; 7.2.3.4 North America Other Services Autism Spectrum Disorders Market by Gender; 7.2.4 North America Market size and forecast, by Location; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Market size and forecast, by Disease; 7.2.5.1.2 Market size and forecast, by Service; 7.2.5.1.3 Market size and forecast, by Location; 7.2.5.2 Canada; 7.2.5.2.1 Market size and forecast, by Disease; 7.2.5.2.2 Market size and forecast, by Service; 7.2.5.2.3 Market size and forecast, by Location; 7.2.5.3 Mexico; 7.2.5.3.1 Market size and forecast, by Disease; 7.2.5.3.2 Market size and forecast, by Service; 7.2.5.3.3 Market size and forecast, by Location; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Disease; 7.3.3 Europe Market size and forecast, by Service; 7.3.3.1 Europe Behavioural Approaches Autism Spectrum Disorders Market by Gender; 7.3.3.2 Europe Early Intervention Autism Spectrum Disorders Market by Gender; 7.3.3.3 Europe Medication Autism Spectrum Disorders Market by Gender; 7.3.3.4 Europe Other Services Autism Spectrum Disorders Market by Gender; 7.3.4 Europe Market size and forecast, by Location; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Market size and forecast, by Disease; 7.3.5.1.2 Market size and forecast, by Service; 7.3.5.1.3 Market size and forecast, by Location; 7.3.5.2 France; 7.3.5.2.1 Market size and forecast, by Disease; 7.3.5.2.2 Market size and forecast, by Service; 7.3.5.2.3 Market size and forecast, by Location; 7.3.5.3 UK; 7.3.5.3.1 Market size and forecast, by Disease; 7.3.5.3.2 Market size and forecast, by Service; 7.3.5.3.3 Market size and forecast, by Location; 7.3.5.4 Italy; 7.3.5.4.1 Market size and forecast, by Disease; 7.3.5.4.2 Market size and forecast, by Service; 7.3.5.4.3 Market size and forecast, by Location; 7.3.5.5 Spain; 7.3.5.5.1 Market size and forecast, by Disease; 7.3.5.5.2 Market size and forecast, by Service; 7.3.5.5.3 Market size and forecast, by Location; 7.3.5.6 Rest of Europe; 7.3.5.6.1 Market size and forecast, by Disease; 7.3.5.6.2 Market size and forecast, by Service; 7.3.5.6.3 Market size and forecast, by Location; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Disease; 7.4.3 Asia-Pacific Market size and forecast, by Service; 7.4.3.1 Asia-Pacific Behavioural Approaches Autism Spectrum Disorders Market by Gender; 7.4.3.2 Asia-Pacific Early Intervention Autism Spectrum Disorders Market by Gender; 7.4.3.3 Asia-Pacific Medication Autism Spectrum Disorders Market by Gender; 7.4.3.4 Asia-Pacific Other Services Autism Spectrum Disorders Market by Gender; 7.4.4 Asia-Pacific Market size and forecast, by Location; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 Japan; 7.4.5.1.1 Market size and forecast, by Disease; 7.4.5.1.2 Market size and forecast, by Service; 7.4.5.1.3 Market size and forecast, by Location; 7.4.5.2 China; 7.4.5.2.1 Market size and forecast, by Disease; 7.4.5.2.2 Market size and forecast, by Service; 7.4.5.2.3 Market size and forecast, by Location; 7.4.5.3 Australia; 7.4.5.3.1 Market size and forecast, by Disease; 7.4.5.3.2 Market size and forecast, by Service; 7.4.5.3.3 Market size and forecast, by Location; 7.4.5.4 India; 7.4.5.4.1 Market size and forecast, by Disease; 7.4.5.4.2 Market size and forecast, by Service; 7.4.5.4.3 Market size and forecast, by Location; 7.4.5.5 Rest of Asia-Pacific; 7.4.5.5.1 Market size and forecast, by Disease; 7.4.5.5.2 Market size and forecast, by Service; 7.4.5.5.3 Market size and forecast, by Location; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Disease; 7.5.3 LAMEA Market size and forecast, by Service; 7.5.3.1 LAMEA Behavioural Approaches Autism Spectrum Disorders Market by Gender; 7.5.3.2 LAMEA Early Intervention Autism Spectrum Disorders Market by Gender; 7.5.3.3 LAMEA Medication Autism Spectrum Disorders Market by Gender; 7.5.3.4 LAMEA Other Services Autism Spectrum Disorders Market by Gender; 7.5.4 LAMEA Market size and forecast, by Location; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Brazil; 7.5.5.1.1 Market size and forecast, by Disease; 7.5.5.1.2 Market size and forecast, by Service; 7.5.5.1.3 Market size and forecast, by Location; 7.5.5.2 Saudi Arabia; 7.5.5.2.1 Market size and forecast, by Disease; 7.5.5.2.2 Market size and forecast, by Service; 7.5.5.2.3 Market size and forecast, by Location; 7.5.5.3 South Africa; 7.5.5.3.1 Market size and forecast, by Disease; 7.5.5.3.2 Market size and forecast, by Service; 7.5.5.3.3 Market size and forecast, by Location; 7.5.5.4 Rest of LAMEA; 7.5.5.4.1 Market size and forecast, by Disease; 7.5.5.4.2 Market size and forecast, by Service; 7.5.5.4.3 Market size and forecast, by Location
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 Abbvie Inc; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 Axial therapeutics; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 Bristol Myers Squibb Co.; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 Cognoa Inc; 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 Curemark LLC; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 dfusion inc.; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 EarliTec Diagnostics Inc; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 Jazz Pharmaceuticals; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Johnson & Johnson; 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments; 9.10 Novartis AG; 9.10.1 Company overview; 9.10.2 Company snapshot; 9.10.3 Operating business segments; 9.10.4 Product portfolio; 9.10.5 Business performance; 9.10.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 2. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR AUTISTIC DISORDER, BY REGION, 2021-2031 ($MILLION); TABLE 3. AUTISM SPECTRUM DISORDERS MARKET FOR AUTISTIC DISORDER, BY COUNTRY, 2021-2031 ($MILLION); TABLE 4. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR ASPERGER SYNDROME, BY REGION, 2021-2031 ($MILLION); TABLE 5. AUTISM SPECTRUM DISORDERS MARKET FOR ASPERGER SYNDROME, BY COUNTRY, 2021-2031 ($MILLION); TABLE 6. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR PERVASIVE DEVELOPMENT DISORDER (PDD), BY REGION, 2021-2031 ($MILLION); TABLE 7. AUTISM SPECTRUM DISORDERS MARKET FOR PERVASIVE DEVELOPMENT DISORDER (PDD), BY COUNTRY, 2021-2031 ($MILLION); TABLE 8. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHER, BY REGION, 2021-2031 ($MILLION); TABLE 9. AUTISM SPECTRUM DISORDERS MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION); TABLE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 11. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR BEHAVIOURAL APPROACHES, BY REGION, 2021-2031 ($MILLION); TABLE 12. AUTISM SPECTRUM DISORDERS MARKET FOR BEHAVIOURAL APPROACHES, BY COUNTRY, 2021-2031 ($MILLION); TABLE 13. GLOBAL BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 14. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION); TABLE 15. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION); TABLE 16. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR EARLY INTERVENTION, BY REGION, 2021-2031 ($MILLION); TABLE 17. AUTISM SPECTRUM DISORDERS MARKET FOR EARLY INTERVENTION, BY COUNTRY, 2021-2031 ($MILLION); TABLE 18. GLOBAL EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 19. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION); TABLE 20. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION); TABLE 21. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR MEDICATION, BY REGION, 2021-2031 ($MILLION); TABLE 22. AUTISM SPECTRUM DISORDERS MARKET FOR MEDICATION, BY COUNTRY, 2021-2031 ($MILLION); TABLE 23. GLOBAL MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 24. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION); TABLE 25. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION); TABLE 26. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHER SERVICES, BY REGION, 2021-2031 ($MILLION); TABLE 27. AUTISM SPECTRUM DISORDERS MARKET FOR OTHER SERVICES, BY COUNTRY, 2021-2031 ($MILLION); TABLE 28. GLOBAL OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 29. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION); TABLE 30. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION); TABLE 31. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 32. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION); TABLE 33. AUTISM SPECTRUM DISORDERS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 34. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR EDUCATION COUNSELLOR CENTER, BY REGION, 2021-2031 ($MILLION); TABLE 35. AUTISM SPECTRUM DISORDERS MARKET FOR EDUCATION COUNSELLOR CENTER, BY COUNTRY, 2021-2031 ($MILLION); TABLE 36. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION); TABLE 37. AUTISM SPECTRUM DISORDERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 38. AUTISM SPECTRUM DISORDERS MARKET, BY REGION, 2021-2031 ($MILLION); TABLE 39. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 40. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 41. NORTH AMERICA BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 42. NORTH AMERICA EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 43. NORTH AMERICA MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 44. NORTH AMERICA OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 45. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 46. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 47. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 48. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 49. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 50. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 51. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 52. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 53. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 54. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 55. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 56. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 57. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 58. EUROPE BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 59. EUROPE EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 60. EUROPE MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 61. EUROPE OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 62. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 63. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 64. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 65. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 66. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 67. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 68. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 69. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 70. UK AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 71. UK AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 72. UK AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 73. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 74. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 75. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 76. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 77. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 78. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 79. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 80. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 81. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 82. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 83. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 84. ASIA-PACIFIC BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 85. ASIA-PACIFIC EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 86. ASIA-PACIFIC MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 87. ASIA-PACIFIC OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 88. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 89. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 90. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 91. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 92. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 93. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 94. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 95. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 96. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 97. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 98. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 99. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 100. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 101. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 102. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 103. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 104. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 105. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 106. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 107. LAMEA BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 108. LAMEA EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 109. LAMEA MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 110. LAMEA OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION); TABLE 111. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 112. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 113. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 114. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 115. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 116. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 117. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 118. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 119. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 120. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 121. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 122. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION); TABLE 123. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION); TABLE 124. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION); TABLE 125.ABBVIE INC: COMPANY SNAPSHOT; TABLE 126.ABBVIE INC: OPERATING SEGMENTS; TABLE 127.ABBVIE INC: PRODUCT PORTFOLIO; TABLE 128.ABBVIE INC: NET SALES,; TABLE 129.ABBVIE INC: KEY STRATERGIES; TABLE 130.AXIAL THERAPEUTICS: COMPANY SNAPSHOT; TABLE 131.AXIAL THERAPEUTICS: OPERATING SEGMENTS; TABLE 132.AXIAL THERAPEUTICS: PRODUCT PORTFOLIO; TABLE 133.AXIAL THERAPEUTICS: NET SALES,; TABLE 134.AXIAL THERAPEUTICS: KEY STRATERGIES; TABLE 135.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT; TABLE 136.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS; TABLE 137.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO; TABLE 138.BRISTOL MYERS SQUIBB CO.: NET SALES,; TABLE 139.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES; TABLE 140.COGNOA INC: COMPANY SNAPSHOT; TABLE 141.COGNOA INC: OPERATING SEGMENTS; TABLE 142.COGNOA INC: PRODUCT PORTFOLIO; TABLE 143.COGNOA INC: NET SALES,; TABLE 144.COGNOA INC: KEY STRATERGIES; TABLE 145.CUREMARK LLC: COMPANY SNAPSHOT; TABLE 146.CUREMARK LLC: OPERATING SEGMENTS; TABLE 147.CUREMARK LLC: PRODUCT PORTFOLIO; TABLE 148.CUREMARK LLC: NET SALES,; TABLE 149.CUREMARK LLC: KEY STRATERGIES; TABLE 150.DFUSION INC.: COMPANY SNAPSHOT; TABLE 151.DFUSION INC.: OPERATING SEGMENTS; TABLE 152.DFUSION INC.: PRODUCT PORTFOLIO; TABLE 153.DFUSION INC.: NET SALES,; TABLE 154.DFUSION INC.: KEY STRATERGIES; TABLE 155.EARLITEC DIAGNOSTICS INC: COMPANY SNAPSHOT; TABLE 156.EARLITEC DIAGNOSTICS INC: OPERATING SEGMENTS; TABLE 157.EARLITEC DIAGNOSTICS INC: PRODUCT PORTFOLIO; TABLE 158.EARLITEC DIAGNOSTICS INC: NET SALES,; TABLE 159.EARLITEC DIAGNOSTICS INC: KEY STRATERGIES; TABLE 160.JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT; TABLE 161.JAZZ PHARMACEUTICALS: OPERATING SEGMENTS; TABLE 162.JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO; TABLE 163.JAZZ PHARMACEUTICALS: NET SALES,; TABLE 164.JAZZ PHARMACEUTICALS: KEY STRATERGIES; TABLE 165.JOHNSON & JOHNSON: COMPANY SNAPSHOT; TABLE 166.JOHNSON & JOHNSON: OPERATING SEGMENTS; TABLE 167.JOHNSON & JOHNSON: PRODUCT PORTFOLIO; TABLE 168.JOHNSON & JOHNSON: NET SALES,; TABLE 169.JOHNSON & JOHNSON: KEY STRATERGIES; TABLE 170.NOVARTIS AG: COMPANY SNAPSHOT; TABLE 171.NOVARTIS AG: OPERATING SEGMENTS; TABLE 172.NOVARTIS AG: PRODUCT PORTFOLIO; TABLE 173.NOVARTIS AG: NET SALES,; TABLE 174.NOVARTIS AG: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.AUTISM SPECTRUM DISORDERS MARKET SEGMENTATION; FIGURE 2.AUTISM SPECTRUM DISORDERS MARKET,2021-2031; FIGURE 3.AUTISM SPECTRUM DISORDERS MARKET,2021-2031; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.AUTISM SPECTRUM DISORDERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 12.AUTISM SPECTRUM DISORDERS MARKET,BY DISEASE,2021(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AUTISTIC DISORDER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASPERGER SYNDROME AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PERVASIVE DEVELOPMENT DISORDER (PDD) AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 17.AUTISM SPECTRUM DISORDERS MARKET,BY SERVICE,2021(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF MEDICATION AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 22.AUTISM SPECTRUM DISORDERS MARKET,BY LOCATION,2021(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 24.COMPARATIVE SHARE ANALYSIS OF EDUCATION COUNSELLOR CENTER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%); FIGURE 26.AUTISM SPECTRUM DISORDERS MARKET BY REGION,2021; FIGURE 27.U.S. AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 28.CANADA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 29.MEXICO AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 30.GERMANY AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 31.FRANCE AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 32.UK AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 33.ITALY AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 34.SPAIN AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 35.REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 36.JAPAN AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 37.CHINA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 38.AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 39.INDIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 40.REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 41.BRAZIL AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 42.SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 43.SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 44.REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION); FIGURE 45. TOP WINNING STRATEGIES, BY YEAR; FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 49.COMPETITIVE DASHBOARD; FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS; FIGURE 51.ABBVIE INC.: NET SALES ,($MILLION); FIGURE 52.AXIAL THERAPEUTICS.: NET SALES ,($MILLION); FIGURE 53.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION); FIGURE 54.COGNOA INC.: NET SALES ,($MILLION); FIGURE 55.CUREMARK LLC.: NET SALES ,($MILLION); FIGURE 56.DFUSION INC..: NET SALES ,($MILLION); FIGURE 57.EARLITEC DIAGNOSTICS INC.: NET SALES ,($MILLION); FIGURE 58.JAZZ PHARMACEUTICALS.: NET SALES ,($MILLION); FIGURE 59.JOHNSON & JOHNSON.: NET SALES ,($MILLION); FIGURE 60.NOVARTIS AG.: NET SALES ,($MILLION)